Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Dosing tuberculosis drugs in young children: the road ahead.

Pasipanodya JG, Gumbo T.

Lancet Child Adolesc Health. 2019 Jul 16. pii: S2352-4642(19)30180-4. doi: 10.1016/S2352-4642(19)30180-4. [Epub ahead of print] No abstract available.

PMID:
31324599
2.

Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.

Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C.

J Antimicrob Chemother. 2019 Jul 4. pii: dkz265. doi: 10.1093/jac/dkz265. [Epub ahead of print]

PMID:
31273386
3.

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.

Dheda K, Lenders L, Srivastava S, Magombedze G, Wainwright H, Raj P, Bush SJ, Pollara G, Steyn R, Davids M, Pooran A, Pennel T, Linegar A, McNerney R, Moodley L, Pasipanodya JG, Turner CT, Noursadeghi M, Warren RM, Wakeland E, Gumbo T.

Am J Respir Crit Care Med. 2019 Jan 29. doi: 10.1164/rccm.201807-1361OC. [Epub ahead of print]

PMID:
30694692
4.

Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T.

J Infect Dis. 2019 Feb 23;219(6):975-985. doi: 10.1093/infdis/jiy587.

PMID:
30597040
5.

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S349-S358. doi: 10.1093/cid/ciy623.

PMID:
30496464
6.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
7.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
8.

Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S284-S292. doi: 10.1093/cid/ciy610.

PMID:
30496458
9.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

PMID:
30496457
10.

Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.

Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T.

Am J Respir Crit Care Med. 2018 Nov 1;198(9):1208-1219. doi: 10.1164/rccm.201711-2333OC.

PMID:
29877726
11.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
12.

Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?

Pasipanodya JG, Gumbo T.

Clin Infect Dis. 2018 Aug 16;67(5):717-718. doi: 10.1093/cid/ciy184. No abstract available.

PMID:
29514180
13.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

14.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, Lee PS, Pasipanodya JG, Dheda K, Gumbo T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02232-17. doi: 10.1128/AAC.02232-17. Print 2018 Feb.

15.

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.

Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. Review.

PMID:
28922813
16.

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i48-i53. doi: 10.1093/jac/dkx307.

PMID:
28922809
17.

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.

Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i36-i42. doi: 10.1093/jac/dkx306.

PMID:
28922808
18.

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. doi: 10.1093/jac/dkx305.

PMID:
28922807
19.

Linezolid as treatment for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i24-i29. doi: 10.1093/jac/dkx304.

PMID:
28922806
20.

pH Conditions under Which Pyrazinamide Works in Humans.

Srivastava S, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00854-17. doi: 10.1128/AAC.00854-17. Print 2017 Sep. No abstract available.

21.

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01206-17. doi: 10.1128/AAC.01206-17. Print 2017 Nov.

22.

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.

Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, Wakeland E, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00751-17. doi: 10.1128/AAC.00751-17. Print 2017 Aug.

23.

Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations.

Hall RG 2nd, Pasipanodya JG, Swancutt MA, Meek C, Leff R, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):552-559. doi: 10.1002/psp4.12208. Epub 2017 Jul 13.

24.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
25.

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.

Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

26.

Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.

Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.

27.

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S95-S101.

28.

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S88-S94.

29.

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.

Deshpande D, Srivastava S, Pasipanodya JG, Bush SJ, Nuermberger E, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S80-S87.

30.

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.

Srivastava S, Deshpande D, Pasipanodya JG, Thomas T, Swaminathan S, Nuermberger E, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S75-S79. Review.

31.

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.

Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S63-S74.

32.

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism.

Rogers Z, Hiruy H, Pasipanodya JG, Mbowane C, Adamson J, Ngotho L, Karim F, Jeena P, Bishai W, Gumbo T.

EBioMedicine. 2016 Sep;11:118-126. doi: 10.1016/j.ebiom.2016.07.031. Epub 2016 Jul 27.

33.

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

Modongo C, Pasipanodya JG, Magazi BT, Srivastava S, Zetola NM, Williams SM, Sirugo G, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5928-32. doi: 10.1128/AAC.00962-16. Print 2016 Oct.

34.

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.

35.

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.

Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5922-7. doi: 10.1128/AAC.00961-16. Print 2016 Oct.

36.

Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C.

BMC Infect Dis. 2016 Jun 1;16:242. doi: 10.1186/s12879-016-1576-1.

37.

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.

Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE, Cirrincione KN, Sherman CM, Swaminathan S, Gumbo T.

EBioMedicine. 2016 Apr;6:126-138. doi: 10.1016/j.ebiom.2016.02.040. Epub 2016 Feb 27.

38.

Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 May 23;60(6):3779-85. doi: 10.1128/AAC.02821-15. Print 2016 Jun.

39.

Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2895-900. doi: 10.1128/AAC.03112-15. Print 2016 May.

40.

Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality.

Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, Myer L, Gumbo T, Mayosi BM.

EBioMedicine. 2015 Sep 21;2(11):1634-9. doi: 10.1016/j.ebiom.2015.09.034. eCollection 2015 Nov.

41.

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease.

Deshpande D, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2157-63. doi: 10.1128/AAC.02854-15. Print 2016 Apr.

42.

Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.

Ferro BE, Srivastava S, Deshpande D, Sherman CM, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2015 Dec 7;60(3):1242-8. doi: 10.1128/AAC.02282-15.

43.

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.

Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T.

Antimicrob Agents Chemother. 2015 Oct;59(10):6337-43. doi: 10.1128/AAC.01050-15. Epub 2015 Jul 27.

44.

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S25-31. doi: 10.1093/cid/civ427.

PMID:
26224769
45.

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.

Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426.

PMID:
26224768
46.

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.

Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425.

PMID:
26224767
47.

Reply to "breakpoints and drug exposure are inevitably closely linked".

Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H.

Antimicrob Agents Chemother. 2015 Feb;59(2):1385. doi: 10.1128/AAC.04688-14. No abstract available.

48.

Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis.

Pasipanodya JG, Srivastava S, Gumbo T.

Pediatr Infect Dis J. 2014 Nov;33(11):1205. doi: 10.1097/INF.0000000000000436. No abstract available.

PMID:
25361414
49.

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H.

Antimicrob Agents Chemother. 2015 Jan;59(1):38-45. doi: 10.1128/AAC.03931-14. Epub 2014 Oct 13.

50.

Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.

Pasipanodya JG, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2015 Jan;70(1):320-1. doi: 10.1093/jac/dku345. Epub 2014 Sep 1. No abstract available.

PMID:
25182065

Supplemental Content

Loading ...
Support Center